Artiva Biotherapeutics plans to construct new GMP manufacturing center. The facility will be an addition to the Artiva’s continued research and GMP manufacturing at its partner GC LabCell’s center.
The new facility designed with 52,000-square-foot will support to develop and provide safe and effective cancer therapies. Moreover, the facility will be in addition to the research and GMP manufacturing at GC LabCell’s state-of-the-art center comprising of research and processing labs and a 50,000-square-foot cell therapy manufacturing facility in the Republic of Korea.
Its features include research and process development laboratories and a multi-suite custom-built Good Manufacturing Practices (GMP) center for the production of NK and CAR-NK therapeutic for the treatment of solid and hematological cancers.
This new facility will help in expanding the leadership position in the evolving field of allogeneic cell therapies.
The construction of the new facility is underway, and expected to be completed in 2022.